Tech Company Financing Transactions
Aer Therapeutics Funding Round
Canaan Partners, Hatteras Venture Partners and OrbiMed joined a $36 million Series A funding round for Aer Therapeutics. The round was announced on 4/14/2023.
Transaction Overview
Company Name
Announced On
4/14/2023
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to advance the development of AER-01, its novel inhaled small molecule mucolytic drug designed to liquefy mucus plugs in the lungs of patients with chronic obstructive pulmonary disease (COPD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 W North St 112
Raleigh, NC 27603
USA
Raleigh, NC 27603
USA
Phone
Website
Email Address
Overview
Aer Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases. Our initial focus is chronic obstructive pulmonary disease (COPD) with other muco-obstructive lung diseases to follow, including asthma, cystic fibrosis, primary ciliary dyskinesia, and non--cystic fibrosis bronchiectasis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jim Shaffer
Browse more venture capital transactions:
Prev: 4/14/2023: Epic Sciences venture capital transaction
Next: 4/14/2023: Next Gate Tech venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs